Green Cross Holdings
KRX:005250
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/FCFF
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Valuation Scenarios
If EV/FCFF returns to its Industry Average (33.4), the stock would be worth ₩-24 691.44 (278% downside from current price).
| Scenario | EV/FCFF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -18.8 | ₩13 900 |
0%
|
| Industry Average | 33.4 | ₩-24 691.44 |
-278%
|
| Country Average | 14.8 | ₩-10 956.26 |
-179%
|
Forward EV/FCFF
Today’s price vs future free cash flow to firm
Peer Comparison
| Market Cap | EV/FCFF | P/E | ||||
|---|---|---|---|---|---|---|
| KR |
|
Green Cross Holdings
KRX:005250
|
645.7B KRW | -18.8 | -9.1 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -211 184.9 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
360.5B USD | 23.4 | 86.1 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
182.2B USD | 27.5 | 23.6 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
159.9B USD | 18.1 | 18.8 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -531.1 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
107.5B USD | 31.2 | 27.2 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
72.5B USD | 13.5 | 16.1 | |
| NL |
|
argenx SE
XBRU:ARGX
|
40.6B EUR | 139.4 | 36.7 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -64.3 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
62.1B AUD | 20.7 | 29.7 |
Market Distribution
| Min | 0 |
| 30th Percentile | 8.7 |
| Median | 14.8 |
| 70th Percentile | 28.4 |
| Max | 4 181.4 |
Other Multiples
Green Cross Holdings
Glance View
Green Cross Holdings Corp. is a holding company of Green Cross Corp. that engages in the manufacture of pharmaceutical products. The company is headquartered in Yongin, Gyeonggi-Do. The Company’s products portfolio consists of prescription drugs, blood derivatives, vaccines, cerebrovascular disease treatment, hunter syndrome drugs, as well as over the counter (OTC) drugs, such as skin disease treatment drugs, allergic cream and others. Its products are used for analgesic, treatment of cerebral thrombosis, hypoalbuminemia, genodermatosis and others, as well as prevention of influenza, prophylaxis of varicella, among others. The firm is also involved in the real estate sales and leasing, as well as construction business.
